# Charles River Laboratories International

> Charles River Laboratories International is a VC fund backing Biotechnology. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Wilmington, United States
- Total investments: 14
- Last investment: Jan 2025
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/8306
- X (Twitter): https://www.twitter.com/criverlabs
- Website: http://www.criver.com
- Facebook: http://www.facebook.com/charlesriverlabs

Charles River Laboratories International is a VC fund in Wilmington focused on Biotechnology and Health Care. Charles River Laboratories International, Inc. provides solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. Segments The company has two segments: Research Models and Services (RMS) and Preclinical Services (PCS), which includes Phase Iclinical services. RESEARCH MODELS AND SERVICES (RMS) The company supplies research models to the drug development industry. With approximately 150 different strains the company engages in the production and sale of research models, principally genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist customers in supporting the use of research models in drug development. With multiple facilities located on three continents (North America, Europe and Asia (Japan)), the company maintains production centers, including a total of approximately 180 barrier rooms or isolator facilities located near its customers. RMS segment comprises Research Models, Research Model Services, and other related products and services

## Contacts

5 contacts available for Charles River Laboratories International. Shizune tracks 9 team members at Charles River Laboratories International. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/charles-river-laboratories-international?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $20M–$31M |
| Series B | $12M–$103M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 36% |
| Health Care | 2 | 14% |
| Life Science | 2 | 14% |
| Therapeutics | 2 | 14% |
| Medical | 1 | 7% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 21% |
| Series B | 3 | 21% |
| Funding Round | 3 | 21% |
| Seed | 1 | 7% |
| Series C | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 29% |
| Canada | 1 | 7% |
| France | 1 | 7% |
| Ireland | 1 | 7% |
| United Kingdom | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anja Tessarz | Scientific Specialist Viral Clearance | 0 | https://shizune.co/investors/profile/anja-tessarz |
| Bill Jefferson | Business Development Director - Safety Assessment | 0 | https://shizune.co/investors/profile/bill-jefferson |
| Chris Lowrie | Senior Director, Lab Sciences | 0 | https://shizune.co/investors/profile/chris-lowrie |
| Gina Mullane | Sr. Vice President Client Experience and Chief Marketing Officer | 0 | https://shizune.co/investors/profile/gina-mullane |
| Greg Mason | Sr. Director, Global Category Procurement, Lab Operations | 0 | https://shizune.co/investors/profile/greg-mason-3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Deciphex | Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $32.1M | Series C | Jan 07, 2025 |  |
| Ability biologics | Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $18M | Seed | Jun 18, 2024 |  |
| Ability biologics | Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $12M | Seed | Dec 06, 2023 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $20M | Series A | Jun 27, 2023 |  |
| iVexSol | iVexSol is a newly formed viral vector manufacturing company | $23.8M | Series A | Jan 26, 2023 |  |
| Wheeler Bio | Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $31M | Series A | Oct 04, 2022 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M |  | Jun 02, 2022 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M | Series A | Jun 02, 2022 |  |
| Deciphex | Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $11.5M | Series B | May 19, 2022 |  |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $15.9M | Series B | Nov 09, 2021 |  |

10 of 14 investments shown.

## Co-investors
- [Alloy Therapeutics](https://shizune.co/investors/profile/alloy-therapeutics) — VC Fund, 3 deals together
- [Dynamk Capital](https://shizune.co/investors/profile/dynamk-capital) — VC Fund, 3 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 3 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 3 deals together
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does Charles River Laboratories International invest in?

Charles River Laboratories International invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Charles River Laboratories International's check size?

Charles River Laboratories International typically joins rounds of $20M–$31M at Series A and $12M–$103M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Charles River Laboratories International participates in.

### How do I contact Charles River Laboratories International?

Public channels for Charles River Laboratories International include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Charles River Laboratories International?

The team at Charles River Laboratories International includes Anja Tessarz (Scientific Specialist Viral Clearance), Bill Jefferson (Business Development Director - Safety Assessment) and Chris Lowrie (Senior Director, Lab Sciences), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co